Sensorion strives to be the first to bring effective drug candidates to patients with inner ear disorders. 

Our efficient, in-house, Research and Development platform:
 - Was developed based on our scientific expertise and years of international research on the inner ear, 
 - Incorporates the most recent scientific advances for in vitro and functional cellular ex vivo assays, in-vivo disease models, pharmacokinetics & pharmacodynamics and toxicology studies,
 - Allows for a reproducible process for developing next-generation products,
 - Is dedicated to discovering first-in-class drug candidates for dysfunctions of the inner ear.


Latest news

  • 06 Jul 2020

    Sensorion appoints Dr Edwin Moses, former Ablynx CEO, as Chairman of the Board. Read

  • 17 Jun 2020

    Sensorion announces initiation of coverage by US investment bank Chardan with a "Buy" recommendation. Read

Patient center

Corporate presentation